Purchase this article with an account.
Glen Jeffery, Jaime Hoh Kam, Aisling Lynch, Rana Begum, Alexander Cunea; A sugar to alleviate the bitter impact of AMD: topical cyclodextrin reduces amyloid beta and inflammation and improves retinal function. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5464.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To clear amyloid beta and reduce inflammation in aged mice (12month) with topical cyclodextrin that is known to have the ability to reduce amyloid in the brain.
Aged mice at 12 months were dosed topically with cyclodextrin (10% in PBS) daily over 3 months in both eyes. Controls were given PBS alone. Before termination they were given ERGs and subsequently the eyes were fixed and processed for immuno staining for amyloid beta, C3 and RPE65. Retinal sections were also stained with Sedan black for their lipid content. In a second group treatment was reduced by 90%.
All animals remained healthy. Amloid beta and inflammation are established at 12 months in old mice on Bruch's membrane and on photoreceptor outer segments. The aged ERG has reduced amplitude and is delayed. Full field ERGs showed significant improvement in both scotopic and photopic ranges after cyclodextrin treatment compared to PBS treated mice. Amyloid beta on Bruch's membrane was redued significantly by 75% and C3 expression significantly reduced by 65%. RPE65 was elevated signficantly by cyclodextrin. Further, the lipid content was reduced on outer segements. Reduced treatment by 90% singnificantly lowered amyloid beta but not iflammation.
Cyclodextrin is a safe sugar known to have the ability to remove amyloid beta, lipid and cholestrol. It is FDA approved as a vehical for drug delivery and also as a food aditive. It has the ability to reach the retina following topical delivery. Our result show that it is an effective agent in clearing retinal deposits, reducing inflammation and improving retinal function.
This PDF is available to Subscribers Only